They contain the same active ingredient semaglutide, tirzepatide or orforglipron but add minor but clinically important modifications such as using a different salt form, adding different inactive ingredients and varying drug concentrations or dosages
Reporting side effects: If you experience a suspected side effect, you or your healthcare professional can report it via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk or through the MHRA Yellow Card app
In many cases, however, the GLP-1 drugs are being compounded in pharmacies that are not required to meet these good manufacturing requirements
SEMA SEMA, a weekly GLP-1RA developed by Novo Nordisk, enhances its affinity for albumin by incorporating two amino acids into human GLP-1, resulting in resistance to degradation in the body
Subsequently, 6 mol/L HCl and n -hexane were added sequentially
Nuclear factor E2-related factor 2 (NRF2) is a transcription factor regulated by oxidative stress